<DOC>
	<DOCNO>NCT01104766</DOCNO>
	<brief_summary>The objective study evaluate efficacy , safety , tolerability cariprazine relative placebo treatment acute exacerbation schizophrenia .</brief_summary>
	<brief_title>Safety Efficacy Cariprazine Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Patients provide informed consent prior study specific procedure Patients currently meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion schizophrenia ( paranoid type , disorganize type , catatonic type undifferentiated type ) , confirm Structured Clinical Interview Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( SCID ) Patients normal physical examination , laboratory , vital sign , and/ electrocardiogram ( ECG ) Patients DSMIVTR diagnosis Schizoaffective disorder , schizophreniform disorder , psychotic disorder schizophrenia , bipolar I II disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Acute Schizophrenia</keyword>
	<keyword>Psychotropic Drugs</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Dopamine Agents</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>